King and Crown Prince offer condolence to Iranian president over the deadly port explosion    stc reports strong first-quarter 2025 results with 11% rise in net profit    Virgin Atlantic celebrates one month of nonstop service between London and Riyadh    Saudi Awwal Bank records SR2.1 billion net profit after zakat and income tax for 1Q25    Mahmoud Abbas appoints Hussein Al-Sheikh as PLO vice president in key succession move    Saudi Arabia's entertainment sector attracts 76 million visitors in 2024    Third round of US-Iran nuclear talks concludes with cautious optimism    Multiple casualties reported after vehicle drives into crowd at Vancouver street festival    Duran leads Al Nassr past Yokohama Marinos into AFC Champions League Elite semi-finals    Al Ahli cruise past Buriram into AFC Champions League Elite semi-finals    Saudi Arabia offers condolences to Iran following deadly Bandar Abbas port explosion    Saudi Arabia deports 12,866 illegal residents in a week    SFDA clears first 44-ton medical shipment for Hajj pilgrims    Ministry of Hajj issued over 150,000 Nusuk cards for the Hajj of 2025    Saudi orchestra to perform at Sydney Opera House in May    Al Hilal thrash Gwangju to reach AFC Champions League Elite semi-finals    Saudi Theater Commission launches its Work and Learn Project in UK    The season has begun — and one comment shook us all    Average life expectancy in Saudi Arabia rises to78.8 years    Famed Philippine film star Nora Aunor dies at 71    Pakistani star's Bollywood return excites fans and riles far right    Veteran Bollywood actor Manoj Kumar dies at 87    Bollywood actress vindicated over boyfriend's death after media hounding    Grand Mufti rules against posting prayers and preaching in mosques on social media    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



KIDNEY CANCER GETS NEW DRUGS
Published in Saudi Press Agency on 04 - 06 - 2006

FOR THE FIRST TIME IN DECADES THERE ARE NEW TREATMENTS AVAILABLE FOR KIDNEY CANCER, AND AS MORE DATA EMERGES ABOUT THEIR EFFICACY, THE COMPETITION LOOKS SET TO HEAT UP, REUTERS REPORTED.
DATA PRESENTED ON SUNDAY AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONFIRMED THE POTENCY OF SUTENT, A DRUG MARKETED BY PFIZER INC. THAT WAS APPROVED BY U.S. REGULATORS IN JANUARY.
FOR THE FIRST TIME, TOO, DATA WAS RELEASED FROM A LATE-STAGE, OR PHASE III, CLINICAL TRIAL OF AN EXPERIMENTAL NEW DRUG FROM WYETH CALLED TEMSIROLIMUS THAT SHOWED IT IMPROVED OVERALL SURVIVAL BY 49 PERCENT IN PATIENTS WITH THE POOREST OUTLOOK.
NEXAVAR, A DRUG MADE BY ONYX PHARMACEUTICALS INC. AND BAYER AG, WAS APPROVED IN DECEMBER AND HAS ALREADY SHOWN THAT IT DOUBLED THE TIME BEFORE THE DISEASE PROGRESSED TO 24 WEEKS FROM 12 WEEKS FOR PATIENTS IN THE PLACEBO GROUP.
ON MONDAY, INVESTIGATORS WILL RELEASE UPDATED SURVIVAL DATA FOR NEXAVAR. THIS TIME LAST YEAR, INTERIM RESULTS OF A PHASE III TRIAL SHOWED THAT NEXAVAR IMPROVED SURVIVAL BY 39 PERCENT, BUT THE RESULTS WERE NOT STATISTICALLY SIGNIFICANT.
WHILE TRIAL INVESTIGATORS FOR SUTENT AND TEMSIROLIMUS EACH CLAIMED SUPERIORITY FOR THEIR DRUG, THEY CONCEDED THAT DIRECT COMPARISONS WERE IMPOSSIBLE AS EACH TRIAL WAS DESIGNED DIFFERENTLY. THE SUTENT TRIAL, FOR EXAMPLE, TESTED PATIENTS WITH A WIDE RANGE OF DISEASE SEVERITY, FROM THOSE WHOSE PROGNOSIS WAS FAVORABLE TO THOSE WHOSE PROGNOSIS WAS POOR. ABOUT 40 PERCENT WERE IN THE MIDDLE.
THE LATE-STAGE CONFIRMATORY TRIAL OF SUTENT SHOWED THE MEDIAN TIME BEFORE WHICH A PATIENT'S DISEASE PROGRESSED WAS 11 MONTHS IN THE SUTENT GROUP COMPARED TO FIVE MONTHS IN THE GROUP TAKING STANDARD INTERFERON THERAPY. THE RESPONSE RATE, A MEASURE OF TUMOR SHRINKAGE, WAS 31 PERCENT IN THE SUTENT GROUP COMPARED TO 6 PERCENT IN THE INTERFERON GROUP.
THE RESULTS DID NOT SHOW WHETHER PATIENTS WHO TOOK SUTENT LIVED LONGER THAN THOSE WHO TOOK THE STANDARD THERAPY.
WYETH, BY CONTRAST, ONLY TESTED PATIENTS WITH THE POOREST PROGNOSIS. ITS TRIAL FOUND PATIENTS WHO WERE TREATED WITH TEMSIROLIMUS ALONE HAD A MEDIAN SURVIVAL TIME OF 10.9 MONTHS, COMPARED WITH 7.3 MONTHS IN THE INTERFERON GROUP.
"IN GENERAL, IN ONCOLOGY, DRUGS THAT WORK IN PATIENTS WITH THE WORST PROGNOSIS WILL WORK AT LEAST AS WELL IF NOT BETTER IN THOSE WITH A BETTER PROGNOSIS," SAID GARY HUDES, DIRECTOR OF THE GENITOURINARY MALIGNANCIES PROGRAM AT FOX CHASE CANCER CENTER IN PHILADELPHIA.
THE WYETH DRUG, WHICH HAS NOT YET BEEN APPROVED, IS IMPORTANT BECAUSE IT IS THE FIRST TO FULLY VALIDATE THE POTENTIAL OF A NEW TARGET FOR CANCER THERAPY CALLED MTOR, HUDES SAID. MTORIS A SIGNALING PROTEIN THAT REGULATES CELL AND BLOOD VESSEL GROWTH.


Clic here to read the story from its source.